FORM 4

Check this box if no longer subject

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549	

BENEFICIAL OWNERSHIP

STATEMENT	OF	CHA	NGES	IN

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

to Section 16. Form 4 or Form 5 obligations may continue. See Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 Instruction 1(b).

Name and Address of Reporting Person* Wedell-Wedellsborg Johan						2. Issuer Name and Ticker or Trading Symbol Y-mAbs Therapeutics, Inc. [YMAB]									tionship of Reportir all applicable) Director Officer (give title		10% Ov		wner	
	(Fir CO GROU! FED STRA	,	Middl	e)		3. Date of Earliest Transaction (Month/Day/Year) 06/03/2021							belov			Other (: below)	вреспу 			
(Street) RUNGS' KYST	G7		<u>.</u>		4. If	Amend	ment, C	Oate (of Ori	iginal F	iled (Moi	nth/Da	ay/Yeaı		6. Indiv Line) X	Form	Joint/Group filed by One filed by Mor on	e Rep	orting Pers	on
(City)	(St		Zip)			_							_							
		Table	: I - I	Non-Deriva				_	_	ed, D					cially	Own	ed			
Date		2. Transaction Date (Month/Day/Ye	Execution Date,		Ti C	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 ar				nd 5) Secu Bene		cially d Following	Forr (D) (Indi	n: Direct or rect (I)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
								С	ode	v	Amount		(A) or (D)	Price		Transa	action(s) 3 and 4)	(1115	u. 4)	(111511.4)
Common	ommon Stock 06/03/202		1	ı		T	S		30,66	6	D	\$33.18	356 ⁽¹⁾	4,415,935			I	By WG Biotech ApS ⁽³⁾		
Common	Stock			06/04/202	1				S		3,841	L	D	\$34.02	286 ⁽²⁾	4,4	12,094		I	By WG Biotech ApS ⁽³⁾
		Tal	ble	II - Derivati (e.g., pu)wne	d			
1. Title of Derivative Security (Instr. 3)	ivative Conversion or Exercise (Month/Day/Year) Frice of Derivative Security Execution Date, (Month/Day/Year) (Month/Day/Year)			saction (Instr.	5. Nur of Deriva Secur Acqui (A) or Dispo of (D) (Instr. and 5)	ative ities red sed 3, 4	Exp (Mo	oiration onth/Da	ay/Year)		7. Title and Amount of Securities Underlying Derivative Security (Inst 3 and 4) Amoun or Numbe of Title Shares		unt per		9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	y	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		

Explanation of Responses:

- 1. This transaction was executed in multiple trades at prices ranging from \$33.165 to \$34.19. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
- 2. This transaction was executed in multiple trades at prices ranging from \$34.00 to \$34.25. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
- 3. Reporting Person is the majority owner of WG Biotech ApS and as such has sole voting and dispositive power with respect to such shares.

/s/ Johan Wedell-Wedellsborg 06/07/2021

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.